Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen in HeFH with CAD
NCT00706849Phase 3Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Jul 2008
- Primary completion
- Dec 2009
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Mipomersen with Placebo (2 arms). Primary endpoints: Percent Change From Baseline in Low-density Lipoprotein Cholesterol at 28 weeks and Low-density Lipoprotein Cholesterol at 28 weeks. Started Jul 2008; status: completed.
02
Drugs
mipomersen
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00706849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706849.